BACKGROUND: Circulating total cholesterol has been inversely associated with cancer risk; however, the role of reverse causation and the associations for high-density lipoprotein (HDL) cholesterol have not been fully characterized. We examined the relationship between serum total and HDL cholesterol and risk of overall and site-specific cancers among 29,093 men in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study cohort. METHODS:Fasting serum total and HDL cholesterol were assayed at baseline, and 7,545 incident cancers were identified during up to 18 years of follow-up. Multivariable proportional hazards models were conducted to estimate relative risks (RR). RESULTS:Higher serum total cholesterol concentration was associated with decreased risk of cancer overall (RR for comparing high versus low quintile, 0.85; 95% confidence interval, 0.79-0.91; P trend <0.001; >276.7 versus <203.9 mg/dL), and the inverse association was particularly evident for cancers of the lung and liver. These associations were no longer significant, however, when cases diagnosed during the first 9 years of follow-up were excluded. Greater HDL cholesterol was also associated with decreased risk of cancer (RR for high versus low quintile, 0.89; 95% confidence interval, 0.83-0.97; P trend = 0.01; >55.3 versus <36.2 mg/dL). The inverse association of HDL cholesterol was evident for cancers of lung, prostate, liver, and the hematopoietic system, and the associations of HDL cholesterol with liver and lung cancers remained after excluding cases diagnosed within 12 years of study entry. CONCLUSION: Our findings suggest that prior observations regarding serum total cholesterol and cancer are largely explained by reverse causation. Although chance and reverse causation may explain some of the inverse HDL associations, we cannot rule out some etiologic role for this lipid fraction.
RCT Entities:
BACKGROUND: Circulating total cholesterol has been inversely associated with cancer risk; however, the role of reverse causation and the associations for high-density lipoprotein (HDL) cholesterol have not been fully characterized. We examined the relationship between serum total and HDL cholesterol and risk of overall and site-specific cancers among 29,093 men in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study cohort. METHODS: Fasting serum total and HDL cholesterol were assayed at baseline, and 7,545 incident cancers were identified during up to 18 years of follow-up. Multivariable proportional hazards models were conducted to estimate relative risks (RR). RESULTS: Higher serum total cholesterol concentration was associated with decreased risk of cancer overall (RR for comparing high versus low quintile, 0.85; 95% confidence interval, 0.79-0.91; P trend <0.001; >276.7 versus <203.9 mg/dL), and the inverse association was particularly evident for cancers of the lung and liver. These associations were no longer significant, however, when cases diagnosed during the first 9 years of follow-up were excluded. Greater HDL cholesterol was also associated with decreased risk of cancer (RR for high versus low quintile, 0.89; 95% confidence interval, 0.83-0.97; P trend = 0.01; >55.3 versus <36.2 mg/dL). The inverse association of HDL cholesterol was evident for cancers of lung, prostate, liver, and the hematopoietic system, and the associations of HDL cholesterol with liver and lung cancers remained after excluding cases diagnosed within 12 years of study entry. CONCLUSION: Our findings suggest that prior observations regarding serum total cholesterol and cancer are largely explained by reverse causation. Although chance and reverse causation may explain some of the inverse HDL associations, we cannot rule out some etiologic role for this lipid fraction.
Authors: Arch G Mainous; Brian J Wells; Richelle J Koopman; Charles J Everett; James M Gill Journal: Am J Epidemiol Date: 2005-06-15 Impact factor: 4.897
Authors: S Dessi; B Batetta; D Pulisci; O Spano; R Cherchi; G Lanfranco; L Tessitore; P Costelli; F M Baccino; C Anchisi Journal: Oncology Date: 1992 Impact factor: 2.935
Authors: P G Moorman; B S Hulka; R A Hiatt; N Krieger; B Newman; J H Vogelman; N Orentreich Journal: Cancer Epidemiol Biomarkers Prev Date: 1998-06 Impact factor: 4.254
Authors: Cari M Kitahara; Amy Berrington de González; Neal D Freedman; Rachel Huxley; Yejin Mok; Sun Ha Jee; Jonathan M Samet Journal: J Clin Oncol Date: 2011-03-21 Impact factor: 44.544
Authors: Yukiko Morimoto; Shannon M Conroy; Nicholas J Ollberding; Susanne M Henning; Adrian A Franke; Lynne R Wilkens; Marc T Goodman; Brenda Y Hernandez; Loïc Le Marchand; Brian E Henderson; Laurence N Kolonel; Gertraud Maskarinec Journal: Cancer Causes Control Date: 2012-08-21 Impact factor: 2.506
Authors: Hugues de Boussac; Aurélien Jc Pommier; Julie Dufour; Amalia Trousson; Françoise Caira; David H Volle; Silvère Baron; Jean-Marc A Lobaccaro Journal: Am J Cancer Res Date: 2013-01-18 Impact factor: 6.166